Results 131 to 140 of about 9,816,425 (315)

An empirical Bayes approach to evaluation of results for a specific region in multiregional clinical trials

, 2013
[[abstract]]To accelerate the drug development process and shorten approval time, the design of multiregional clinical trials (MRCTs) incorporates subjects from many countries/regions around the world under the same protocol.
Huang, Y;Chang, WJ;Hsiao, CF
core   +1 more source

Jingfang Granules for prevention of alcohol-induced hangover: a randomized, double-blind, crossover trial in healthy volunteers

Frontiers in Pharmacology
IntroductionJingfang Granules (JFG), a classical traditional Chinese medicine formula comprising 11 botanical drugs, have traditionally been prescribed to dispel cold and eliminate dampness. This study aimed to clinically evaluate the efficacy and safety
Feng Wu, Yuyang Dai, Siyang Ni, Jing Zhang, Xiaojun Hu, Ying Han, Ying Jiao, Huan Lu, Laichun Lu   +8 more
doaj   +1 more source

Structure‐forward targeting of claudins with synthetic binders

FEBS Letters, EarlyView.
Claudins form the paracellular barriers between epithelial and endothelial tissues at tight junctions and are targets for molecular binders with the goal of modulating barrier permeability. Claudin‐binding molecules are relevant in drug delivery or in altering claudin interactions with disease‐causing proteins.
Alex J. Vecchio
wiley   +1 more source

Proteo-genomic analyses in relatively lean Chinese adults identify proteins and pathways that affect general and central adiposity levels

Communications Biology
Adiposity is an established risk factor for multiple diseases, but the causal relationships of different adiposity types with circulating protein biomarkers have not been systematically investigated.
Andri Iona, Pang Yao, Alfred Pozarickij, Christiana Kartsonaki, Saredo Said, Neil Wright, Kuang Lin, Iona Millwood, Hannah Fry, Mohsen Mazidi, Baihan Wang, Yiping Chen, Huaidong Du, Ling Yang, Daniel Avery, Dan Schmidt, Dianjianyi Sun, Pei Pei, Jun Lv, Canqing Yu, Michael Hill, Junshi Chen, Fiona Bragg, Derrick Bennett, Robin Walters, Liming Li, Robert Clarke, Zhengming Chen, China Kadoorie Biobank Collaborative Group   +28 more
doaj   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source

Patient and public involvement and engagement in the ASCEND PLUS trial: reflections from the design of a streamlined and decentralised clinical trial

Trials
Introduction ASCEND PLUS is a randomised controlled trial assessing the effects of oral semaglutide on the primary prevention of cardiovascular events in around 20,000 individuals with type 2 diabetes in the UK.
Muram El-Nayir, Rohan Wijesurendra, David Preiss, Marion Mafham, Leandros Tsiotos, Sadman Islam, Anne Whitehouse, Sophia Wilkinson, Hannah Freeman, Ryonfa Lee, Wojciech Brudlo, Genna Bobby, Bryony Jenkins, Robert Humphrey, Amy Mallorie, Andrew Toal, Elnora C. Barker, Dianna Moylan, Graeme Thomson, Firoza Davies, Hameed Khan, Ian Allotey, Susan Dickie, John Roberts   +23 more
doaj   +1 more source

Partial depletion of plasminogen activator inhibitor‐1 decreases subcutaneous fat cell hypertrophy and liver cholesterol in high‐fat‐fed female mice

FEBS Letters, EarlyView.
Obesity raises blood levels of PAI‐1, a protein linked to metabolic dysfunction‐associated steatotic liver disease in people with obesity. In female mice fed a high‐fat diet, partially lowering PAI‐1 led to smaller subcutaneous fat cells and lower liver cholesterol, without changing body weight or insulin sensitivity.
Claudia E. Ramirez Bustamante, Robert Sharp, Pradip K. Saha, Elizabeth S. Anaya, Elizabeth L. Lieu, Evelyn L. de Groot, Pooja Patel, Mi Jeong Heo, Aaron R. Cox, Kang Ho Kim, Sean M. Hartig   +10 more
wiley   +1 more source

Clinical trials overseen by US FDA

, 2010
The Office of Inspector General, US Department of Health and Human Services, released a report in June 2010 entitled Challenges to FDA’s Ability to Monitor and Inspect Foreign Clinical Trials.
Karlberg, JPE
core  

Ligand‐dependent transcriptional heterogeneity in cell cycle gene expression delays G1/S entry

FEBS Letters, EarlyView.
EGF and HRG induce distinct G1/S progression programs in ErbB2‐amplified BT474 breast cancer cells. Despite activating the potent ErbB2–ErbB3 heterodimer, HRG does not accelerate cell‐cycle entry. Instead, EGF promotes earlier restriction‐point passage via ERK–FOS signaling, whereas HRG activates the AKT–MYC axis, driving transcriptional heterogeneity ...
Ririn Rahmala Febri, Ayaka Nagasato‐Ichikawa, Keita Iida, Shuhei Kimura, Akira Imamoto, Mariko Okada   +5 more
wiley   +1 more source

A randomized, double-masked, placebo controlled clinical trial of multivitamin supplementation for age-related lens opacities. Clinical trial of nutritional supplements and age-related cataract report n° 3

, 2008
OBJECTIVE: To evaluate the effect of a multivitamin/mineral supplement on development or progression of age-related lens opacities. DESIGN: Randomized, double-masked, single center, placebo-controlled clinical trial.
Ferrigno L., supplements, CAMPARINI, Monica, Sperduto RD, Rosmini F, Maraini G, Ferris F, Clinical Trial of nutritional, age related cataract STUDY GROUP, Clemons TE   +9 more
core